PRNewsWire
26 May 2026, 10:45 UTC · 2h ago
Source · https://www.prnewswire.com/news-releases/lilly-announces-three-acquisitions-to-build-infectious-disease-portfolio-302781404.html
Read source
Search tags
Story key points
3 claims · impact-rated
Eli Lilly is acquiring Curevo for up to $1.5 billion to obtain a next-generation shingles vaccine candidate that showed reduced side effects in Phase 2 trials. — Acquiring a Phase 2 asset with proven tolerability improvements over the standard of care provides a clear path to market expansion and revenue growth.
+0.40Eli Lilly is acquiring LimmaTech Biologics for up to $780 million to develop vaccines against antimicrobial-resistant bacterial pathogens, including a Phase 1 S. aureus candidate. — Expanding into the antimicrobial resistance space addresses a critical unmet medical need, though early-stage (Phase 1) assets carry higher risk.
+0.30Eli Lilly is acquiring Vaccine Company to utilize In Vivo Nanoparticle (IVN) technology, with a lead Phase 1-ready candidate targeting the Epstein-Barr Virus (EBV). — The acquisition of a new technology platform and an EBV candidate offers long-term strategic value and pipeline diversification.
+0.20Impact vectors
1 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Ticker attribution
Model heads
The company is strategically expanding its infectious disease portfolio through three targeted acquisitions to address high-need health problems.
No ticker relationship head found.
